Swiss Regulatory Authority Accepts Marketing Authorization
Application for Ceftobiprole for Assessment
Basel, Switzerland, October 8, 2007 - Basilea Pharmaceutica Ltd.
(SWX:BSLN) announced today that Swissmedic has accepted for
assessment the marketing authorization application of ceftobiprole
for the treatment of complicated skin and soft tissue infections
(cSSTI) including diabetic foot infections. The application is
subject to an accelerated review. The regulatory dossier was
submitted by Basilea's license partner Janssen-Cilag AG, a Johnson &
Johnson company.
Swissmedic had previously granted accelerated assessment of the
marketing authorization application ("Beschleunigtes
Zulassungsverfahren") for ceftobiprole for the treatment of
complicated skin and soft tissue infections.
Ceftobiprole is currently under review by regulatory authorities in
the U.S., Canada and the European Union.
Ceftobiprole is being developed through an exclusive worldwide
collaboration between Basilea Pharmaceutica Ltd. and Cilag GmbH
International.
About Basilea
Basilea Pharmaceutica Ltd. is an integrated biopharmaceutical company
headquartered in Basel, Switzerland, listed on the SWX Swiss Exchange
(SWX:BSLN). Basilea is currently focused on the research, development
and commercialization of new antibacterial, antifungal and
dermatology drugs in the hospital and specialty care setting.
Disclaimer
This communication is intended for information to the financial
community only (investors and/or potential investors and their
advisors) and expressly or implicitly contains certain
forward-looking statements concerning Basilea Pharmaceutica Ltd. and
its business. Such statements involve certain known and unknown
risks, uncertainties and other factors, which could cause the actual
results, financial condition, performance or achievements of Basilea
Pharmaceutica Ltd. to be materially different from any future
results, performance or achievements expressed or implied by such
forward-looking statements. Basilea Pharmaceutica Ltd. is providing
this communication as of this date and does not undertake to update
any forward-looking statements contained herein as a result of new
information, future events or otherwise.
For further information, please contact:
+-----------------------------------------------------------------+
| General Information | Investor Relations |
|--------------------------------+--------------------------------|
| information@basilea.com | Dr. Barbara Zink |
| | investor_relations@basilea.com |
+-----------------------------------------------------------------+
This press release can be downloaded from www.basilea.com
The press release can also be downloaded from the following link:
